Showing results (131-140 of 322) with videos related to
Sort By:
Pageof 33
BJU International|November 8, 2008
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeMichael K Ng, Nicholas Van As, Karen Thomas, et al.Biological Psychiatry|September 27, 2005
Impact of selenium on mood and quality of life: a randomized, controlled trialMargaret Rayman, Alexander Thompson, Margaret Warren-Perry, et al.European Urology|March 12, 2014
Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancerJane M Blazeby, Emma Hall, Neil K Aaronson, et al.Physics and Imaging in Radiation Oncology|July 14, 2021
Factors affecting accuracy and precision in ultrasound guided radiotherapyAlexander Grimwood, Karen Thomas, Sally Kember, et al.Clinical Genitourinary Cancer|March 8, 2020
Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT TrialEdward Cox, Pedro Saramago, John Kelly, et al.International Journal of Radiation Oncology, Biology, Physics|January 13, 2026
2-year outcomes of the SPARC phase II trial: Simultaneous focal boost with stereotactic radiotherapy for localised intermediate to high-risk prostate cancerBinnaz Yasar, Yae-Eun Suh, Ewan Chapman, et al.International Journal of Radiation Oncology, Biology, Physics|March 18, 2024
Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 TrialBinnaz Yasar, Yae-Eun Suh, Ewan Chapman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADTLaurence Klotz, Chris O'Callaghan, Keyue Ding, et al.European Urology|January 14, 2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agentsCarmel J Pezaro, Aurelius G Omlin, Amelia Altavilla, et al.Stroke (Hoboken, N.J.)|July 6, 2026
Diagnostic Accuracy of Ischemia and Hemorrhage on Cone-Beam CT Immediately After Endovascular ThrombectomyLovisa Landström, Henrik Andersson, Mattias Drake, et al.Pageof 33